Search

This volume explores several aspects of how antibodies mediate their activity in vivo, ranging from cancer immunotherapy to autoimmunity, infection, and vaccination. Divided into seven chapters, it provides in-depth insights into how antibodies and especially the antibody fragment crystallizable (Fc) domain modulate immune responses and antibody activity. The book begins by discussing evolutionary aspects of how the family of Fc receptors that are the key molecules for antibody activity evolved. In turn, it addresses the molecular and cellular pathways underlying IgG activity in cancer immunotherapy, and focuses on how IgG glycosylation regulates IgG and IgE activity in autoimmunity, allergy and infection. In closing, it presents strategies for developing novel antibody-based vaccination approaches. The book is intended for a very broad readership, including graduate students, postdocs and principal investigators with a basic grasp of immunology.

First published in 2006, the bestselling Wintrobe's Atlas of Clinical Hematologyhas now been comprehensively updated by a brand-new editorial team to bring you state-of-the-art pictorial coverage of the complete range of hematologic conditions. Thousands of meticulous, full-color images capture the characteristic appearance of each pathologic entity, and concise descriptions point out features of diagnostic importance. The result is a peerless reference to facilitate confident diagnosis in hematology.

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients'immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Catalytic antibodies have attracted attention because they can combine exquisite specificity with permanent and potent antigen inactivation. The field has enjoyed a renaissance in recent years due to the discovery of antibodies with comparatively efficient peptidase and nuclease activities. In principle, antibody catalysis could serve as a platform technology for curing hitherto intractable human diseases, a potential which is exemplified by the availability of catalysts capable of cleaving biologically important targets such as HIV coat proteins. Equally important, catalytic antibodies to physiologically important target autoantigens have been identified in disease. This volume addresses fundamental questions concerning the immunological genesis of the catalytic activity in antibodies, its relationship with classical antigen binding activity, and the biochemical mechanisms involved in catalysis. The contents reflect three main challenges in the field, i.e. to delineate the biological functions of catalytic antibodies in autoimmune disease; to isolate therapy-grade antibody catalysts with sufficient specificity and turnover to permit rapid removal of microbial and tumor antigens; and to develop immunogens that recruit immature catalyst-producing B cells into the clonal selection pathway and induce adaptive improvements of the catalytic function. Well-edited and up-to-date, this book reviews the current knowledge in the field and explores ways by which natural and engineered catalytic activities can be harnessed for medical applications. It should therefore be of special interest to immunologists, biochemists, biotechnologists, rheumatologists and pathologists.

The last decade has witnessed remarkable developments in antibody research and its therapeutic applications. With the methods of molecular biology it is now possible to manipulate the specificities and activities of antibody molecules to generate an almost limitless array of structures for both basic investigations and the clinical setting. The contributions to this volume cover all three domains of the antibody: the variable regions, the relatively neglected but crucial hinge, and the constant region. These studies provide critical structural and functional information about antibodies, while also pointing the way to the construction of molecules with enhanced or even novel properties. Bringing together major experts on antibody engineering, this book is highly recommended to faculty, postdoctoral fellows and graduate students in molecular biology, microbiology, immunology, cancer research and genetics.